Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C→T polymorphism in MTHFR
- 1 March 2010
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Hypertension
- Vol. 28 (3), 478-486
- https://doi.org/10.1097/hjh.0b013e328334c126
Abstract
The purpose was to examine the effect of intervention with riboflavin (a cofactor for MTHFR) on blood pressure in patients homozygous (TT genotype) for the common 677C-->T polymorphism in MTHFR. We investigated 197 premature cardiovascular disease patients, prescreened for the MTHFR 677C-->T polymorphism, from an original cohort of 404 to select those with the TT genotype (n = 60) and a similar number with heterozygous (CT; n = 85) or wild-type (CC; n = 75) genotypes. Of these, 181 completed an intervention in which participants were randomized within each genotype group to receive 1.6 mg per day riboflavin or placebo for 16 weeks. Among patients taking one or more antihypertensive drugs at recruitment (82%), we observed that target blood pressure (<140/90 mmHg) had been achieved in only 37% patients with the TT genotype compared with 59% with the CT and 64% with the CC genotype (P < 0.001). Riboflavin intervention reduced mean blood pressure specifically in those with the TT genotype (from 144/87 to 131/80 mmHg; P < 0.05 systolic; P < 0.05 diastolic), with no response observed in the other genotype groups. Riboflavin is effective in reducing blood pressure specifically in patients with the MTHFR 677 TT genotype. The findings, if confirmed, may have important implications for the prevention and treatment of hypertension.Keywords
This publication has 38 references indexed in Scilit:
- The Methylenetetrahydrofolate Reductase 677C→T Polymorphism as a Modulator of a B Vitamin Network with Major Effects on Homocysteine MetabolismAmerican Journal of Human Genetics, 2007
- Riboflavin Lowers Homocysteine in Individuals Homozygous for the MTHFR 677C→T PolymorphismCirculation, 2006
- Meta-analysis of MTHFR 677C→ T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate?BMJ, 2005
- Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wideJournal of Medical Genetics, 2003
- Homocysteine and cardiovascular disease: evidence on causality from a meta-analysisBMJ, 2002
- MTHFR 677C→T Polymorphism and Risk of Coronary Heart DiseaseJAMA, 2002
- Impaired functioning of thermolabile methylenetetrahydrofolate reductase is dependent on riboflavin status: implications for riboflavin requirementsThe American Journal of Clinical Nutrition, 2002
- Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductaseProceedings of the National Academy of Sciences of the United States of America, 2001
- Relation Between Folate Status, a Common Mutation in Methylenetetrahydrofolate Reductase, and Plasma Homocysteine ConcentrationsCirculation, 1996
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995